BrainChip (BRN) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
16 Jul, 2026Opening remarks and agenda
Acknowledgement of traditional custodians and welcome to attendees, both in-person and virtual.
Introductions of board members, executives, and auditors; confirmation of meeting quorum and procedural guidance.
Explanation of voting and Q&A processes for both physical and online participants.
Board and executive committee updates
Board composition discussed, including skills and diversity; board unanimously did not endorse a self-nominated director candidate.
Non-executive directors deferred annual grants to 2026 to reinforce confidence in the company.
Financial performance review
Shareholders questioned the use of $60 million in funds, share price decline, and lack of major commercial license agreements.
$9 million bookings target for 2025 set as CEO performance metric, with bookings defined as closed contracts or POs.
Revenue recognition rules explained; bookings may not immediately translate to revenue.
Goal to achieve cash flow neutrality over the next 1–2 years; not expected in 2025.
Latest events from BrainChip
- Cash outflows improved, R&D consolidated, and new collaborations drive commercialization efforts.BRN
Q2 202410 Jun 2026 - Strategic growth, new edge AI products, and governance dominated, with robust shareholder engagement.BRN
AGM 202611 May 2026 - Revenue up 72% and net loss reduced, with strong capital raises and edge AI focus for 2025.BRN
H2 20246 Apr 2026 - Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.BRN
H2 20256 Apr 2026 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 202529 Jan 2026 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 20251 Dec 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation10 Nov 2025 - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation19 Oct 2025 - Revenue soared 859% and net loss narrowed, with new funding and partnerships fueling growth.BRN
H1 202521 Aug 2025